Gary Raskob to Neoplasms
This is a "connection" page, showing publications Gary Raskob has written about Neoplasms.
Connection Strength
3.267
-
Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. J Thromb Haemost. 2022 10; 20(10):2366-2378.
Score: 0.445
-
Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. Oncologist. 2021 01; 26(1):e8-e16.
Score: 0.396
-
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874.
Score: 0.360
-
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.
Score: 0.337
-
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
Score: 0.322
-
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug; 3(8):e379-87.
Score: 0.291
-
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov 25; 114(6):1268-76.
Score: 0.274
-
Redefining clinical venous thromboembolism phenotypes: a?novel approach using latent class analysis. J Thromb Haemost. 2023 03; 21(3):573-585.
Score: 0.114
-
Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thromb Haemost. 2020 Jun; 120(6):924-936.
Score: 0.096
-
Edoxaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 07 05; 379(1):95-96.
Score: 0.084
-
Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul; 118(7):1270-1278.
Score: 0.083
-
Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thromb Haemost. 2018 01; 118(1):174-181.
Score: 0.081
-
Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res. 2016 07 01; 76(13):3671-5.
Score: 0.073
-
The US Cancer Moonshot initiative. Lancet Oncol. 2016 05; 17(5):e178-80.
Score: 0.072
-
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec; 13(12):2187-91.
Score: 0.070
-
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb Haemost. 2010 Jul; 104(1):86-91.
Score: 0.048
-
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
Score: 0.044
-
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 01; 25(34):5490-505.
Score: 0.040
-
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec; 119(12):1062-72.
Score: 0.037